Illumina's stock surged 6.01% intraday on Friday, driven by multiple positive catalysts that boosted investor sentiment toward the genetic sequencing company.

The rally was fueled by industry merger and acquisition dynamics and a patent infringement lawsuit filed by Illumina against Oxford Nanopore's sequencing platforms. Additionally, the company's solid fourth-quarter earnings provided fundamental support, with revenue reaching $1.08 billion and earnings per share of $1.25 exceeding analyst expectations.

Further bolstering the stock were multiple analyst price target increases from major financial institutions including Evercore ISI, JP Morgan, and Barclays, reflecting growing optimism about Illumina's future performance.